急性痛风是一种常见的自身炎症性关节炎,由滑膜关节软组织内单钠尿酸盐(monosodium urate,MSU)晶体沉积引起,尿酸盐通过半胱天冬酶(caspase)激活单核巨噬细胞分泌白细胞介素-1β(interleukin-1β,IL-1β),从而介导痛风性炎症反应。由于...急性痛风是一种常见的自身炎症性关节炎,由滑膜关节软组织内单钠尿酸盐(monosodium urate,MSU)晶体沉积引起,尿酸盐通过半胱天冬酶(caspase)激活单核巨噬细胞分泌白细胞介素-1β(interleukin-1β,IL-1β),从而介导痛风性炎症反应。由于痛风常见的一些合并症,目前首选治疗药物的使用受到许多限制。2016年更新的欧洲风湿病防治联合会(European League Against Rheumatism,EULAR)指南建议对急性痛风频繁发作以及难以使用常规疗法治疗的患者使用IL-1受体拮抗剂(interleukin-1 receptor antagonist,IL-1Ra)。阿那白滞素(anakinra)是一种重组非糖基化的人IL-1Ra,目前已被美国食品药品管理局(FDA)批准上市,并用于治疗类风湿关节炎等疾病多年,相比于其他IL-1Ra,anakinra的性价比更高。近年来anakinra治疗急性痛风的研究日益增多,研究结果支持其在治疗急性痛风发作中的有效性。本文就其对急性痛风的作用与治疗研究作一综述。展开更多
美国丹佛关节炎临床、临床研究组的Dr Michael Schiff等人研究显示Anakinra可有效治疗风湿性关节炎(RA)。 Anakinra也称Kineret,是重组白介素-1受体拮抗剂。其治疗RA的机理与以往的治疗方法完全不同,它是通过对白细胞介素-1的拮抗来进...美国丹佛关节炎临床、临床研究组的Dr Michael Schiff等人研究显示Anakinra可有效治疗风湿性关节炎(RA)。 Anakinra也称Kineret,是重组白介素-1受体拮抗剂。其治疗RA的机理与以往的治疗方法完全不同,它是通过对白细胞介素-1的拮抗来进行治疗的。可用于中重度活动性RA和那些其它治疗方法无效的患者。展开更多
Currently clinicians all around the world are experiencing a pandemic caused by severe acute respiratory syndrome coronavirus 2(SARS-CoV-2).The clinical presentation of this pathology includes fever,dry cough,fatigue ...Currently clinicians all around the world are experiencing a pandemic caused by severe acute respiratory syndrome coronavirus 2(SARS-CoV-2).The clinical presentation of this pathology includes fever,dry cough,fatigue and acute respiratory distress syndrome that can lead to death infected patients.Current studies on coronavirus disease 2019(COVID-19)continue to highlight the urgent need for an effective therapy.Numerous therapeutic strategies have been used until now but,to date,there is no specific effective treatment for SARS-CoV-2 infection.Elevated inflammatory cytokines have been reported in patients with COVID-19.Evidence suggests that elevated cytokine levels,reflecting a hyperinflammatory response secondary to SARS-CoV-2 infection,are responsible for multi-organ damage in patients with COVID-19.For these reason,numerous randomized clinical trials are currently underway to explore the effectiveness of biopharmaceutical drugs,such as,interleukin-1 blockers,interleukin-6 inhibitors,Janus kinase inhibitors,in COVID-19.The aim of the present paper is to briefly summarize the pathogenetic rationale and the state of the art of therapeutic strategy blocking hyperinflammation.展开更多
文摘急性痛风是一种常见的自身炎症性关节炎,由滑膜关节软组织内单钠尿酸盐(monosodium urate,MSU)晶体沉积引起,尿酸盐通过半胱天冬酶(caspase)激活单核巨噬细胞分泌白细胞介素-1β(interleukin-1β,IL-1β),从而介导痛风性炎症反应。由于痛风常见的一些合并症,目前首选治疗药物的使用受到许多限制。2016年更新的欧洲风湿病防治联合会(European League Against Rheumatism,EULAR)指南建议对急性痛风频繁发作以及难以使用常规疗法治疗的患者使用IL-1受体拮抗剂(interleukin-1 receptor antagonist,IL-1Ra)。阿那白滞素(anakinra)是一种重组非糖基化的人IL-1Ra,目前已被美国食品药品管理局(FDA)批准上市,并用于治疗类风湿关节炎等疾病多年,相比于其他IL-1Ra,anakinra的性价比更高。近年来anakinra治疗急性痛风的研究日益增多,研究结果支持其在治疗急性痛风发作中的有效性。本文就其对急性痛风的作用与治疗研究作一综述。
文摘美国丹佛关节炎临床、临床研究组的Dr Michael Schiff等人研究显示Anakinra可有效治疗风湿性关节炎(RA)。 Anakinra也称Kineret,是重组白介素-1受体拮抗剂。其治疗RA的机理与以往的治疗方法完全不同,它是通过对白细胞介素-1的拮抗来进行治疗的。可用于中重度活动性RA和那些其它治疗方法无效的患者。
文摘Currently clinicians all around the world are experiencing a pandemic caused by severe acute respiratory syndrome coronavirus 2(SARS-CoV-2).The clinical presentation of this pathology includes fever,dry cough,fatigue and acute respiratory distress syndrome that can lead to death infected patients.Current studies on coronavirus disease 2019(COVID-19)continue to highlight the urgent need for an effective therapy.Numerous therapeutic strategies have been used until now but,to date,there is no specific effective treatment for SARS-CoV-2 infection.Elevated inflammatory cytokines have been reported in patients with COVID-19.Evidence suggests that elevated cytokine levels,reflecting a hyperinflammatory response secondary to SARS-CoV-2 infection,are responsible for multi-organ damage in patients with COVID-19.For these reason,numerous randomized clinical trials are currently underway to explore the effectiveness of biopharmaceutical drugs,such as,interleukin-1 blockers,interleukin-6 inhibitors,Janus kinase inhibitors,in COVID-19.The aim of the present paper is to briefly summarize the pathogenetic rationale and the state of the art of therapeutic strategy blocking hyperinflammation.
